مباشر

FierceBiotechKordata Dynamics launches with neural-focused AI clinical trial model Clinical OMICsDual CA19-9 Threshold Improves Risk Stratification in Pancreatic Cancer Clinical OMICsCD169-Positive Macrophages Attacking Melanoma Imaged in Living Tissue Clinical OMICsGuardant Nabs Key ACS Nod and Liquid Biopsy Approval Clinical OMICsAI Foundation Model Maps Tumor Mutations to Predict Cancer Therapy Response BioPharma DiveCardio drugmaker Kardigan plans to go public BioPharma DiveKailera’s three-pronged obesity shot shows promise in early trial BioPharma DiveApogee eczema drugs gets Blackstone backing, heads to Phase 3 Endpoints NewsAstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave Endpoints NewsApogee secures Blackstone capital to move Dupixent rival into Phase 3 Clinical OMICsPrecancerous Adenomas Alter Gut Microbiome for Long Period FierceBiotechD&D sees fibrosis improvements, MASH resolution after rolling dice on GLP-1 drug

BioWorld ٢٧ مايو ٢٠٢٦

Work underway on vaccines, antivirals against rare Bundibugyo Ebola outbreak

Less than two weeks after the outbreak was officially declared, animal studies of a newly designed vaccine against the Bundibugyo Ebola virus are now underway i...

Less than two weeks after the outbreak was officially declared, animal studies of a newly designed vaccine against the Bundibugyo Ebola virus are now underway in the U.S. and U.K., and the Serum Institute of India is standing ready to manufacture the vaccine for clinical trials. If the animal tests are positive, the vaccine will be ready for clinical trials in two to three months.